Trial Profile
Phase 2 Study Of The Effects Of Open-Label CP-690,550 And Double-Blind Atorvastatin On Lipids In Patients With Active Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary) ; Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- Sponsors Pfizer
- 01 Feb 2017 Results of post-hoc analysis from pooled data of six phase II studies, six phase III studies and two long term extension studies published in the JCR: Journal of Clinical Rheumatology.
- 31 Jan 2017 Long term safety results (n=6194 data cut off 31 Mar 2015) of 2 phase I, 9 phase II, 6 phase III and 2 long term extension studies (NCT01262118, NCT01484561, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT00413699, NCT00661661) in adult patients with active Rheumatoid arthritis published in the Annals of the Rheumatic Diseases
- 17 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.